Anti-TIM-3 antibody
View Patent ↗The present invention provides an anti-human TIM-3 antibody having high ADCC activity or antibody fragment thereof by screening a monoclonal antibody or antibody fragment thereof which binds to the amino acid sequence of the extracellular region of TIM-3 or its three-dimensional structure and exhibits ADCC activity; a hybridoma which produces the antibody; a DNA encoding the antibody; a vector comprising the DNA; a transformant which is obtainable by introducing the vector; a method for producing the antibody or the antibody fragment thereof which comprises using the hybridoma or the transformant; a therapeutic agent and a diagnostic agent comprising the antibody or the antibody fragment thereof as an active ingredient.
1. A monoclonal antibody or an antigen-binding fragment thereof, which is one selected from the following (a) to (e):
(a) a monoclonal antibody or an antigen-binding fragment thereof, each comprising a heavy chain (H chain) and a light chain (L chain), wherein complementarity determining regions (CDRs) 1 to 3 of said H chain comprises the amino acid sequences of SEQ ID NOs: 1 to 3, respectively, and CDRs 1 to 3 of said L chain comprises the amino acid sequences of SEQ ID NOs: 4 to 6, respectively,
(b) a monoclonal antibody or an antigen-binding fragment thereof, each comprising an H chain and a L chain, wherein CDRs 1 to 3 of said H chain comprises the amino acid sequences of SEQ ID NOs: 11 to 13, respectively, and CDRs 1 to 3 of said L chain comprises the amino acid sequences of SEQ ID NOs: 14 to 16, respectively,
(c) a monoclonal antibody or an antigen-binding fragment thereof, each comprising an H chain and a L chain, wherein CDRs 1 to 3 of said H chain comprises the amino acid sequences of SEQ ID NOs: 21 to 23, respectively, and CDRs 1 to 3 of said L chain comprises the amino acid sequences of SEQ ID NOs: 24 to 26, respectively,
(d) a monoclonal antibody or an antigen-binding fragment thereof, each comprising an H chain variable region (VH) and a L chain variable region (VL), wherein said VH and VL comprises the amino acid sequences of SEQ ID NO: 8 and SEQ ID NO: 10, respectively, and
(e) a monoclonal antibody or an antigen-binding fragment thereof, each comprising VH and VL, wherein said VH and VL comprises the amino acid sequences of SEQ ID NO: 18 and SEQ ID NO: 20, respectively.
2. The monoclonal antibody or antigen-binding fragment thereof according to claim 1 , which is a recombinant antibody.
3. The monoclonal antibody or antigen-binding fragment thereof according to claim 2 , which is a recombinant antibody selected from the group consisting of a human chimeric antibody, a humanized antibody and a human antibody.
4. The monoclonal antibody or the antigen-binding fragment thereof according to claim 1 , which binds to the amino acid residues at positions 67 to 105, the amino acid residues at positions 67 to 96 or the amino acid residues at positions 67 to 87 in the amino acid sequence of IgV domain of human T-cell immunoglobulin and mucin domain containing molecule-3 (TIM-3) of SEQ ID NO: 53.
5. The antigen-binding fragment according to claim 1 , which is selected from the group consisting of a Fab, a Fab′, a F(ab′) 2 , a single chain antibody (scFv), a dimerized V region (diabody), a disulfide stabilized V region (dsFv) and a peptide comprising CDR.
6. The monoclonal antibody or antigen-binding fragment thereof according to claim 1 , which comprises a heavy chain (H chain) and a light chain (L chain), wherein complementarity determining regions (CDRs) 1 to 3 of said H chain comprises the amino acid sequences of SEQ ID NOs: 1 to 3, respectively, and CDRs 1 to 3 of said L chain comprises the amino acid sequences of SEQ ID NOs: 4 to 6, respectively.
7. The monoclonal antibody or antigen-binding fragment thereof according to claim 1 , which comprises an H chain and a L chain, wherein CDRs 1 to 3 of said H chain comprises the amino acid sequences of SEQ ID NOs: 21 to 23, respectively, and CDRs 1 to 3 of said L chain comprises the amino acid sequences of SEQ ID NOs: 24 to 26, respectively.
8. A pharmaceutical composition, comprising the monoclonal antibody or the antigen-binding fragment thereof according to claim 1 and a pharmaceutically acceptable carrier.
9. A process for producing a monoclonal antibody or an antigen binding fragment thereof that binds to an extracellular region of human T-cell immunoglobulin and mucin domain containing molecule-3 (TIM 3), said process comprising culturing a transformant comprising a DNA encoding the monoclonal antibody or the antigen binding fragment thereof according to claim 1 in a culture medium to form and accumulate the monoclonal antibody or the antigen binding fragment thereof, and recovering the monoclonal antibody or the antigen-binding fragment thereof from the culture.
10. A method for immunologically detecting or measuring human T-cell immunoglobulin and mucin domain containing molecule-3 (TIM-3) which comprises using the monoclonal antibody or the antigen-binding fragment thereof according to claim 1 .
11. A method for diagnosing a disease relating to a human T-cell immunoglobulin and mucin domain containing molecule-3 (TIM-3 positive cell, which comprises detecting or measuring a human TIM-3 positive cell or human TIM-3, using the monoclonal antibody or the antigen-binding fragment thereof according to claim 1 .